NASDAQ · VTRSHealthcarePharmaceuticals

Viatris financials

$18.12−0.82%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
Revenue$14.30B$14.74B$15.43B$16.26B$17.89B$11.95B
Gross profit$5.01B$5.62B$6.44B$6.50B$5.58B$3.80B
Gross margin35.1%38.2%41.7%40.0%31.2%31.8%
Operating income-$2.66B$10.1M$766.2M$1.61B-$34.0M-$210.8M
Net income-$3.51B-$634.2M$54.7M$2.08B-$1.27B-$669.9M
Net margin−24.6%−4.3%0.4%12.8%−7.1%−5.6%
Diluted EPS$-3.00$-0.53$0.05$1.71$-1.05$-1.11
EBITDA$3.00B$3.58B$4.20B$4.65B$4.80B$2.11B
Operating cash flow$2.32B$2.30B$2.90B$3.00B$3.02B$1.23B
Free cash flow$1.94B$1.98B$2.52B$2.55B$2.56B$988.8M
Diluted shares1,171.6M1,193.3M1,206.9M1,217.4M1,208.8M601.2M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$1.32B$734.8M$991.9M$1.26B$701.2M$844.4M
Short-term investments$0.00$0.00$0.00$0.00——
Total debt$14.41B$14.05B$18.13B$19.27B$23.09B$25.84B
Total assets$37.19B$41.50B$47.69B$50.02B$54.84B$61.55B
Total liabilities$22.48B$22.87B$27.22B$28.95B$34.35B$38.60B
Shareholders' equity$14.71B$18.64B$20.47B$21.07B$20.49B$22.95B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology